

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.)*

CYTOKLONAL PHARMACEUTICS

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23282G105

(CUSIP Number)

Paul F. Byrne c/o Janssen-Meyers Associates, L.P. 17 State Street,
NY, NY 10004
(212) 742-4200

(Name, Address and Telephone Number of Person Authorized to Receive Notices
and
Communications)

12/31/97

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to
report the
acquisition
which is the
subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the
following box ____.

Check the following box if a fee is being paid with the statement ____.

(A fee is not required only if the
reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five
percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto
reporting beneficial ownership of five percent or less
of such class.) (Sec Rule 13d-7.)

Note: Six copies of this statement, including all exhibits,
should be filed with the Commission. See Rule
13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled
out for a reporting person's initial filing on
this form with
respect to the subject class of securities,
and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the
remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities
of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

1. Name of Reporting Person

Peter Janssen

S.S. or I.R.S. Identification No. of Above Person

2. Check the Appropriate Box if a Member of a Group
(See Instructions before filling out)

a. _____ b. _____

3. SEC USE ONLY

4. Source of Funds (See instructions before filling out).

5. Check Box if Disclosure of Legal Proceedings is
Required Pursuant to Items
2(d) or 2(e).

6. Citizenship or Place of Organization

USA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
(Questions 7 - 10)

7. Sole Voting Power
830,000 shares Common Stock

8. Shared Voting Power

9. Sole Dispositive Power

830,000 shares Common Stock

10. Shared Dispositive Power

11. Aggregate Amount Beneficially Owned by Each Reporting Person

830,000 shares Common Stock

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
(See instructions before filling out)

13. Percent of Class Represented by Amount in Row (11)

10%

14. Type of Reporting Person (See instructions before filling out)

Shareholder
